Skip to main content

Advertisement

SpringerLink
Log in

Multidisciplinary Approach in the Treatment of Resistant Hypertension

  • Resistant Hypertension (E Pimenta, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

With its high prevalence and the eminent number of undetected or poorly controlled patients, the management of arterial hypertension is still a challenging task. Uncontrolled blood pressure is the major adjustable risk factor for cardiovascular end organ damage for coronary heart disease, heart failure, stroke, and renal disease. Patients with resistant hypertension often need a multidisciplinary approach in order to control their blood pressure sustainably. In cooperation with hypertension specialists, the underlying cause for therapy resistance should be evaluated. Pseudohypertension, white coat hypertension, and non-adherence need to be addressed. The medication can often be optimized and simplified. Reducing the number of pills per day can enhance the drug-adherence remarkably. The multidisciplinary evaluation of secondary causes of hypertension includes an endocrinological work-up, ruling out relevant sleeping disorders, and renal diagnostics. If there are no causative treatments possible and pharmacological and non-pharmacological measurements are not sufficient to control the blood pressure, one has to consider multidisciplinary approaches bringing nurses, pharmacists, dieticians, physiotherapists, social workers, psychologists, and community health workers onboard. Utilizing various strategies might improve medication management, patient follow-up, adherence, and self-management. Interventional therapy such as renal renervation, baroreflex activation therapy, or carotid body modulation is the final option that can be discussed with interventional active colleagues. However, large randomized controlled trials proving a benefit of these interventional therapies are still missing. The use of these still experimental approaches should be restricted to randomized controlled trials accordingly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Collaborators GBDRF, Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–323.

    Article  Google Scholar 

  2. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801–12.

    Article  PubMed  Google Scholar 

  3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.

    Article  PubMed  Google Scholar 

  4. • Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens. 2015;29(4):247–53. The German epidemiology study “DEGS1” reveals an increase in awareness of hypertension from 69.4 to 82.3% from 1998 to 2011, with treatment rates increasing from 54.8 to 71.8%. Even though control rate (office BP < 140/90 mmHg) increased from 22.7 to 51.2%, almost 50% of hypertensive individuals remain uncontrolled. This indicates a persistent unmet need in health care management with a high socio-economic impact.

    Article  CAS  PubMed  Google Scholar 

  5. In Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. 2011: London.

  6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.

    Article  CAS  PubMed  Google Scholar 

  7. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

  8. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.

    Article  PubMed  Google Scholar 

  9. Doroszko A, Janus A, Szahidewicz-Krupska E, Mazur G, Derkacz A. Resistant hypertension. Adv Clin Exp Med. 2016;25(1):173–83.

    Article  PubMed  Google Scholar 

  10. International Society for, C, C American Association of Medical, Chronotherapeutics, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30(3):355–410.

    Article  Google Scholar 

  11. Group, S R, Wright Jr JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  Google Scholar 

  12. Myers MG, Cloutier L, Gelfer M, Padwal RS, Kaczorowski J. Blood pressure measurement in the post-SPRINT era: a Canadian perspective. Hypertension. 2016;68(1):e1–3.

    Article  CAS  PubMed  Google Scholar 

  13. Kjeldsen SE, Mancia G. Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg. Eur Heart J Cardiovasc Pharmacother. 2016;2(2):79–80.

    Article  PubMed  Google Scholar 

  14. • Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74. In this observational study, uncontrolled hypertensive individuals were referred to a hypertension center. After optimization of treatment regiment, 108 out of 375 patients met the criteria for resistant hypertension. After excluding secondary causes, 76 patients remained, of which 40 (53%) were non-adherent, tested through urinary metabolite analysis. The authors concluded that non-adherence was the most common cause for resistant hypertension; twice as common within the group of resistant hypertensive than secondary causes. This study highlights two major issues in treatment of hypertension: First, optimal treatment regiments are not always in place when facing apparent resistant hypertension and correction can improve blood pressure control rates significantly. Second, non-adherence appears to be a major factor in resistant hypertension. Measures to assess adherence and improve adherence might therefore be beneficial, especially in this group of patients.

    Article  CAS  PubMed  Google Scholar 

  15. Rabbia, F., C. Fulcheri, S. Di Monaco, M. Covella, E. Perlo, M. Pappaccogli, and F. Veglio (2016) Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs. High Blood Press Cardiovasc Prev

  16. Bunker, J., C.L. Chang, N. Chapman, N. Poulter, S. Thom, L. Thornton-Jones, and P. Sever (2016) True resistant hypertension following observed drug ingestion: a systematic evaluation. J Clin Hypertens (Greenwich)

  17. Calleja Rivero JL, Zerpa F, Rivera L. Fixed-dose versus separate drug combinations for antihypertensive treatment: literature review. Medwave. 2016;16(8):e6549.

    Article  PubMed  Google Scholar 

  18. Bramlage, P., H. Sims, J. Minguet, and C. Ferrero (2016) The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiol

  19. Simonyi, G., T. Ferenci, S. Alfoldi, and C. Farsang (2016) Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. J Int Med Res

  20. • Azizi M, Pereira H, Hamdidouche I, et al. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the Renal Denervation for Hypertension (DENERHTN) trial. Circulation. 2016;134(12):847–57. The study examined the “add-on” effect of renal denervation to standardized stepped-care antihypertensive treatment. A low adherence of about 50% was found in both groups in the 6-month follow-up analysis. Renal denervation as an add-on to standardized stepped-care antihypertensive treatment resulted in a greater decrease in blood pressure than standardized stepped-care antihypertensive treatment alone. This study highlights a possible alternative for improved and persistent blood pressure control through device-based treatment options in regards to non-adherence in drug therapy. The blood pressure lowering effect of renal denervation seems to be independent from drug adherence.

    Article  CAS  PubMed  Google Scholar 

  21. Messerli FH, Bangalore S. Treatment-resistant hypertension: another Cinderella story. Eur Heart J. 2013;34(16):1175–7.

    Article  PubMed  Google Scholar 

  22. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. McComb MN, Chao JY, Ng TM. Direct vasodilators and sympatholytic agents. J Cardiovasc Pharmacol Ther. 2016;21(1):3–19.

    Article  CAS  PubMed  Google Scholar 

  24. • Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. The PATHWAY-2 trial compared the addition of either spironolactone, bisoprolol, doxazosin, or placebo to a consisting triple antihypertensive therapy (mostly RAAS inhibition, calcium channel blocker, and diuretics) in resistant hypertensive individuals. The investigators could show that the addition of spironolactone was accompanied with a significantly higher reduction in systolic blood pressure as compared to bisoprolol, doxazosin, and placebo. However, the treatment period of 6 weeks on lower and 6 weeks on higher dose might be too short to evaluate possible adverse effects in long-term treatment.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu G, Zheng XX, Xu YL, Lu J, Hui RT, Huang XH. Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis. J Hum Hypertens. 2015;29(3):159–66.

    Article  CAS  PubMed  Google Scholar 

  26. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376–85.

    Article  PubMed  Google Scholar 

  27. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J. 2002;4(1):17–20.

    CAS  PubMed  Google Scholar 

  28. Maiolino G, Azzolini M, Rossi GP. Mineralocorticoid receptor antagonists therapy in resistant hypertension: time to implement guidelines! Front Cardiovasc Med. 2015;2:3.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006;19(7):750–5.

    Article  CAS  PubMed  Google Scholar 

  30. Oliveras A, Armario P, Clara A, Sans-Atxer L, Vazquez S, Pascual J, De la Sierra A. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study—a randomized controlled trial. J Hypertens. 2016;34(9):1863–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–54.

    Article  PubMed  Google Scholar 

  32. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65.

    Article  PubMed  Google Scholar 

  33. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36(40):2686–95.

    Article  PubMed  Google Scholar 

  34. Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68(1):293–301.

    Article  PubMed  Google Scholar 

  35. Mousa AY, AbuRahma AF, Bozzay J, Broce M, Bates M. Update on intervention versus medical therapy for atherosclerotic renal artery stenosis. J Vasc Surg. 2015;61(6):1613–23.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Muxfeldt ES, de Souza F, Margallo VS, Salles GF. Cardiovascular and renal complications in patients with resistant hypertension. Curr Hypertens Rep. 2014;16(9):471.

    Article  PubMed  Google Scholar 

  37. Himmelfarb CR, Commodore-Mensah Y, Hill MN. Expanding the role of nurses to improve hypertension care and control globally. Ann Glob Health. 2016;82(2):243–53.

    Article  PubMed  Google Scholar 

  38. Hinderliter AL, Sherwood A, Craighead LW, Lin PH, Watkins L, Babyak MA, Blumenthal JA. The long-term effects of lifestyle change on blood pressure: one-year follow-up of the ENCORE study. Am J Hypertens. 2014;27(5):734–41.

    Article  PubMed  Google Scholar 

  39. Blumenthal JA, Sherwood A, Smith PJ, et al. Lifestyle modification for resistant hypertension: the TRIUMPH randomized clinical trial. Am Heart J. 2015;170(5):986–94. e5

    Article  PubMed  PubMed Central  Google Scholar 

  40. Nieuwlaat, R., N. Wilczynski, T. Navarro, et al. (2014) Interventions for enhancing medication adherence. Cochrane Database Syst Rev (11): CD000011

  41. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144(7):485–95.

    Article  PubMed  Google Scholar 

  42. Hess PL, Reingold JS, Jones J, et al. Barbershops as hypertension detection, referral, and follow-up centers for black men. Hypertension. 2007;49(5):1040–6.

    Article  CAS  PubMed  Google Scholar 

  43. Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014;78(6):1238–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sheppard JP, Schwartz CL, Tucker KL, McManus RJ. Modern management and diagnosis of hypertension in the United Kingdom: home care and self-care. Ann Glob Health. 2016;82(2):274–87.

    Article  PubMed  Google Scholar 

  45. McManus RJ, Mant J, Bray EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376(9736):163–72.

    Article  PubMed  Google Scholar 

  46. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.

    Article  CAS  PubMed  Google Scholar 

  47. Persu A, Kjeldsen S, Staessen JA, Azizi M. Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep. 2016;18(1):6.

    Article  PubMed  Google Scholar 

  48. Silva JD, Costa M, Gersh BJ, Goncalves L. Renal denervation in the era of HTN-3. Comprehensive review and glimpse into the future. J Am Soc Hypertens. 2016;10(8):656–70.

    Article  PubMed  Google Scholar 

  49. Potthoff SA, Rump LC, Vonend O. The “resistant hypertension team”: focus on a multidisciplinary approach to hypertension. EuroIntervention. 2013;9(Suppl R):R48–53.

    Article  PubMed  Google Scholar 

  50. Hering, D., C. Schultz, and M.P. Schlaich (2016) Device therapies for resistant hypertension. Clin Ther

  51. Li P, Nader M, Arunagiri K, Papademetriou V. Device-based therapy for drug-resistant hypertension: an update. Curr Hypertens Rep. 2016;18(8):64.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Clinic Duesseldorf, Department of Nephrology, Medical Faculty, Heinrich-Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany

    S. A. Potthoff & O. Vonend

  2. Nierenzentrum Wiesbaden, von-Leyden Str. 23, 65191, Wiesbaden, Germany

    O. Vonend

Authors
  1. S. A. Potthoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Vonend
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. A. Potthoff.

Ethics declarations

Conflict of Interest

Drs. Potthoff and Vonend declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Resistant Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Potthoff, S.A., Vonend, O. Multidisciplinary Approach in the Treatment of Resistant Hypertension. Curr Hypertens Rep 19, 9 (2017). https://doi.org/10.1007/s11906-017-0698-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-017-0698-1

Keywords

Search

Navigation